Scholars@Duke

• Background
• 

  Education, Training, & Certifications

  • M.D., Ohio State University 1974
• 

  Duke Appointment History

  • Chief of the Medical Oncology and Transplantation Division in the Department of Medicine, Medicine, Medical Oncology, Medicine 2003 - 2013
  • Associate Director of Clinical Research, Comprehensive Cancer Center, Duke Cancer Institute, Institutes and Centers 1995 - 2007
  • Clinical Chief of the Medical Oncology and Transplantation Division, Medicine, Medical Oncology, Medicine 2003 - 2004
  • Acting Director for Clinical Services for the Division of Medical Oncology in the Department of Medicine, Medicine, Clinical Science Departments 1998 - 2003
  • Associate Professor of Medicine, Medicine, Medical Oncology, Medicine 1992 - 1997
  • Associate in the Department of Medicine, Medicine, Clinical Science Departments 1978 - 1982
• Research
• 

  Selected Grants

  • BR.31 awarded by Clinipace, Inc. 2016 - 2026
  • NCI National Clinical Trials Network (UG1) awarded by National Institutes of Health 2019 - 2025
  • HELSINN - ANAM-17-21 awarded by Helsinn Healthcare S.A. 2019 - 2024
  • A phase II, Open-label, single-arm study to assess the safety and efficacy of AZD9291 in patients with locally advanced/ awarded by AstraZeneca AB 2014 - 2019
  • NCI National Clinical Trials Network U10 (Year 5) awarded by National Institutes of Health 2014 - 2019
  • Identification of Genetic Determinates for Disparities in African American Patients with Non-Small Cell Lung Cancer awarded by V Foundation for Cancer Research 2016 - 2018
  • Phase II anetumab ravtansine as 2nd line treatment for malignant pleural mesothelioma awarded by Bayer HealthCare AG 2016 - 2018
  • EMD Serono, Inc. Education Event awarded by EMD Serono Inc 2017
  • TIGER 1: A randomized, open-label, phase II study of CO-1686 or Erlotinib as first-line treatment of patients with EGFR-Mutant advanced non-small cell lung cancer awarded by Clovis Oncology, Inc. 2015 - 2017
  • A phase 2, randomized, double-blind study comparing Tremelimumab to placebo in Second- or third-line treatment of subjec awarded by MedImmune, Inc. 2013 - 2017
  • A phase III, double-blind, randomized, placebo-controlled study to assess the efficacy and safety of selumetinib (AZD624 awarded by AstraZeneca Pharmaceuticals, LP 2014 - 2016
  • FibroGen, Inc. FGCL-3019-073 awarded by Fibrogen, Inc. 2015 - 2016
  • MORAb-009-021 awarded by Morphotek, Inc 2016
  • A Decision Aid with HRQL Assessment to Reduce Costs in the Treatment of NSCLC awarded by University of Virginia - Charlottesville 2012 - 2015
  • Clinical Oncology Research Career Development Program awarded by National Institutes of Health 2009 - 2015
  • ANC Study Group awarded by Fred Hutchinson Cancer Research Center 2014
  • Cancer and Leukemia Group B awarded by National Institutes of Health 2009 - 2014
  • Research Training in Cancer Biology and Therapy awarded by National Institutes of Health 1978 - 2013
  • Refining and Validating Genomic Signatures in Lung Cancer awarded by National Institutes of Health 2009 - 2010
  • Prospective Validation of Genomic Signatures of Chemosensitivity in NSCLC awarded by National Institutes of Health 2009 - 2010
  • Biomarker Studies for Novel Anti-Cancer Agents awarded by National Institutes of Health 2003 - 2008
  • Phase I/II Trial of ZD1839 and Celecoxib in Ex-Smokers awarded by National Institutes of Health 2002 - 2007
  • Measurement of Hypoxia in Non-Small Cell Lung Carcinoma awarded by National Institutes of Health 2002 - 2006
  • Dexasome Based Immunotherapy of Lung Cancer awarded by National Institutes of Health 2001 - 2004
  • Cancer and Leukemia Group B awarded by National Institutes of Health 1998 - 2003
  • Cancer and Leukemia Group B awarded by National Institutes of Health 1988 - 2003
  • Cancer and Leukemia Group B awarded by National Institutes of Health 1988 - 2003
  • Using Plasma TGFB1 Levels to Escalate Radiotherapy Doses awarded by National Institutes of Health 2000 - 2003
  • Cancer Center Core Support Grant awarded by National Institutes of Health 1976 - 1998
  • Comprehensive Cancer Center Core Support Grant awarded by National Institutes of Health 1976 - 1998
  • Comprehensive Cancer Center Core Support Grant awarded by National Institutes of Health 1976 - 1998
  • Cancer And Leukemia Group B awarded by National Institutes of Health 1993 - 1998
  • Cancer And Leukemia Group B awarded by National Institutes of Health 1988 - 1998
• Publications & Artistic Works
• 

  Selected Publications

  • Books

    • Lyman, G. H., and J. Crawford. Cancer supportive care: Advances in therapeutic strategies, 2008.
    • Lyman, G. H., and J. Crawford. Preface, 2008.

  • Academic Articles

    • Crawford, Jeffrey. “What are the criteria for response to cachexia treatment?.” Ann Palliat Med 8, no. 1 (January 2019): 43–49. https://doi.org/10.21037/apm.2018.12.08.
       Full Text  Link to Item
    • Ramalingam, Sendhilnathan, Michaela A. Dinan, and Jeffrey Crawford. “Survival Comparison in Patients with Stage IV Lung Cancer in Academic versus Community Centers in the United States..” Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer 13, no. 12 (December 2018): 1842–50. https://doi.org/10.1016/j.jtho.2018.09.007.
       Full Text
    • Denduluri, Neelima, Gary H. Lyman, Yunfei Wang, Phuong Khanh Morrow, Richard Barron, Debra Patt, Debajyoti Bhowmik, et al. “Chemotherapy Dose Intensity and Overall Survival Among Patients With Advanced Breast or Ovarian Cancer..” Clinical Breast Cancer 18, no. 5 (October 2018): 380–86. https://doi.org/10.1016/j.clbc.2018.02.003.
       Full Text
    • Arantes, Luiz H., Jeffrey Crawford, Pere Gascon, Mark Latymer, Vincent Launay-Vacher, Catherine Rolland, Florian Scotte, and Jay Wish. “A quick scoping review of efficacy, safety, economic, and health-related quality-of-life outcomes of short- and long-acting erythropoiesis-stimulating agents in the treatment of chemotherapy-induced anemia and chronic kidney disease anemia..” Critical Reviews in Oncology/Hematology 129 (September 2018): 79–90. https://doi.org/10.1016/j.critrevonc.2018.06.010.
       Full Text
    • Kinsey, Emily, Elizabeth Ajazi, Xiaofei Wang, Mary Ann Mayzie Johnston, and Jeffrey Crawford. “Predictors of Physical and Functional Loss in Advanced-Stage Lung Cancer Patients Receiving Platinum Chemotherapy..” J Thorac Oncol 13, no. 9 (September 2018): 1294–1301. https://doi.org/10.1016/j.jtho.2018.05.029.
       Full Text  Link to Item
    • Vlahovic, Gordana, Kellen L. Meadows, Ace J. Hatch, Jingquan Jia, Andrew B. Nixon, Hope E. Uronis, Michael A. Morse, et al. “A Phase I Trial of the IGF-1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer..” The Oncologist 23, no. 7 (July 2018): 782–90. https://doi.org/10.1634/theoncologist.2016-0377.
       Full Text
    • Crawford, Jeffrey. “Cancer cachexia: Are we ready to take a step forward?.” Cancer 124, no. 3 (February 2018): 456–58. https://doi.org/10.1002/cncr.31126.
       Full Text
    • Dale, David C., Jeffrey Crawford, Zandra Klippel, Maureen Reiner, Timothy Osslund, Ellen Fan, Phuong Khanh Morrow, Kim Allcott, and Gary H. Lyman. “A systematic literature review of the efficacy, effectiveness, and safety of filgrastim..” Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer 26, no. 1 (January 2018): 7–20. https://doi.org/10.1007/s00520-017-3854-x.
       Full Text
    • Crawford, Jeffrey, Pamela Sue Becker, James O. Armitage, Douglas W. Blayney, Julio Chavez, Peter Curtin, Shira Dinner, et al. “Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology..” Journal of the National Comprehensive Cancer Network : Jnccn 15, no. 12 (December 2017): 1520–41. https://doi.org/10.6004/jnccn.2017.0175.
       Full Text
    • Yi, John S., Neal Ready, Patrick Healy, Chelsae Dumbauld, Robyn Osborne, Mark Berry, Debra Shoemaker, et al. “Immune Activation in Early-Stage Non-Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab..” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 23, no. 24 (December 2017): 7474–82. https://doi.org/10.1158/1078-0432.CCR-17-2005.
       Full Text
    • Le-Rademacher, Jennifer G., Jeffrey Crawford, William J. Evans, and Aminah Jatoi. “Overcoming obstacles in the design of cancer anorexia/weight loss trials..” Critical Reviews in Oncology/Hematology 117 (September 2017): 30–37. https://doi.org/10.1016/j.critrevonc.2017.06.008.
       Full Text
    • Tandberg, Daniel J., Chris R. Kelsey, Thomas A. D’Amico, Jeffrey Crawford, Junzo P. Chino, Betty C. Tong, Neal E. Ready, and Ato Wright. “Patterns of Failure After Surgery for Non-Small-cell Lung Cancer Invading the Chest Wall..” Clinical Lung Cancer 18, no. 4 (July 2017): e259–65. https://doi.org/10.1016/j.cllc.2016.11.008.
       Full Text
    • Winckworth-Prejsnar, Katy, Elizabeth A. Nardi, Lisa Korin Lentz, Jeffrey A. Crawford, C Lyn Fitzgerald, and Robert W. Carlson. “Developments in Molecular Testing and Biosimilars..” Journal of the National Comprehensive Cancer Network : Jnccn 15, no. 6 (June 2017): 772–82. https://doi.org/10.6004/jnccn.2017.0109.
       Full Text
    • Baggstrom, M. Q., M. A. Socinski, X. F. Wang, L. Gu, T. E. Stinchcombe, M. J. Edelman, S. Baker, et al. “Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non–Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study—CALGB 30607 (Alliance).” Journal of Thoracic Oncology 12, no. 5 (May 1, 2017): 843–49. https://doi.org/10.1016/j.jtho.2017.01.022.
       Full Text
    • Riedel, Richard F., Kellen L. Meadows, Paula H. Lee, Michael A. Morse, Hope E. Uronis, Gerard C. Blobe, Daniel J. George, et al. “Phase I study of pazopanib plus TH-302 in advanced solid tumors..” Cancer Chemotherapy and Pharmacology 79, no. 3 (March 2017): 611–19. https://doi.org/10.1007/s00280-017-3256-2.
       Full Text
    • Wang, Xiaofei, Xiaoyi Wang, Lydia Hodgson, Stephen L. George, Daniel J. Sargent, Nate R. Foster, Apar Kishor Ganti, et al. “Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials..” Oncologist 22, no. 2 (February 2017): 189–98. https://doi.org/10.1634/theoncologist.2016-0121.
       Full Text  Link to Item
    • Kelley, Michael J., Gautam Jha, Debra Shoemaker, James E. Herndon, Lin Gu, William T. Barry, Jeffrey Crawford, and Neal Ready. “Phase II Study of Dasatinib in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer..” Cancer Investigation 35, no. 1 (January 2017): 32–35. https://doi.org/10.1080/07357907.2016.1253710.
       Full Text
    • De Ruysscher, D., B. Lueza, C. Le Péchoux, D. H. Johnson, M. O’Brien, N. Murray, S. Spiro, et al. “Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer: usefulness of the individual patient data meta-analysis..” Annals of Oncology : Official Journal of the European Society for Medical Oncology 27, no. 10 (October 2016): 1818–28. https://doi.org/10.1093/annonc/mdw263.
       Full Text
    • Boyer, Matthew J., Lin Gu, Xiaofei Wang, Chris R. Kelsey, David S. Yoo, Mark W. Onaitis, Frank R. Dunphy, Jeffrey Crawford, Neal E. Ready, and Joseph K. Salama. “Toxicity of definitive and post-operative radiation following ipilimumab in non-small cell lung cancer..” Lung Cancer (Amsterdam, Netherlands) 98 (August 2016): 76–78. https://doi.org/10.1016/j.lungcan.2016.05.014.
       Full Text
    • Crawford, Jeffrey, Carla M. M. Prado, Mary Ann Johnston, Richard J. Gralla, Ryan P. Taylor, Michael L. Hancock, and James T. Dalton. “Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials)..” Curr Oncol Rep 18, no. 6 (June 2016). https://doi.org/10.1007/s11912-016-0522-0.
       Full Text  Link to Item
    • Crawford, Jeffrey. “Clinical results in cachexia therapeutics..” Curr Opin Clin Nutr Metab Care 19, no. 3 (May 2016): 199–204. https://doi.org/10.1097/MCO.0000000000000274.
       Full Text  Link to Item
    • Raftopoulos, Haralambos, Abderrahmane Laadem, Paul J. Hesketh, Jerome Goldschmidt, Nashat Gabrail, Cynthia Osborne, Muhammad Ali, et al. “Sotatercept (ACE-011) for the treatment of chemotherapy-induced anemia in patients with metastatic breast cancer or advanced or metastatic solid tumors treated with platinum-based chemotherapeutic regimens: results from two phase 2 studies..” Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer 24, no. 4 (April 2016): 1517–25. https://doi.org/10.1007/s00520-015-2929-9.
       Full Text
    • Salama, Joseph K., Lin Gu, Xiaofei Wang, Herbert H. Pang, Jeffrey A. Bogart, Jeffrey Crawford, Steven E. Schild, Everett E. Vokes, and Neal E. Ready. “Positive Interaction between Prophylactic Cranial Irradiation and Maintenance Sunitinib for Untreated Extensive-Stage Small Cell Lung Cancer Patients After Standard Chemotherapy: A Secondary Analysis of CALGB 30504 (ALLIANCE)..” J Thorac Oncol 11, no. 3 (March 2016): 361–69. https://doi.org/10.1016/j.jtho.2015.11.001.
       Full Text  Link to Item
    • Crawford, Jeffrey, Paul Wheatley-Price, and Josephine Louella Feliciano. “Treatment of Lung Cancer in Medically Compromised Patients..” American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting 35 (January 2016): e484–91. https://doi.org/10.1200/edbk_158713.
       Full Text
    • Fearon, Kch, J. M. Argiles, V. E. Baracos, R. Bernabei, Ajs Coats, J. Crawford, N. E. Deutz, et al. “Request for regulatory guidance for cancer cachexia intervention trials..” J Cachexia Sarcopenia Muscle 6, no. 4 (December 2015): 272–74. https://doi.org/10.1002/jcsm.12083.
       Full Text  Open Access Copy  Link to Item
    • Wang, Xiaofei, Lin Gu, Ying Zhang, Daniel J. Sargent, William Richards, Apar Kishor Ganti, Jeffery Crawford, et al. “Validation of survival prognostic models for non-small-cell lung cancer in stage- and age-specific groups..” Lung Cancer (Amsterdam, Netherlands) 90, no. 2 (November 2015): 281–87. https://doi.org/10.1016/j.lungcan.2015.08.007.
       Full Text
    • Smith, Thomas J., Kari Bohlke, Gary H. Lyman, Kenneth R. Carson, Jeffrey Crawford, Scott J. Cross, John M. Goldberg, et al. “Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update..” J Clin Oncol 33, no. 28 (October 1, 2015): 3199–3212. https://doi.org/10.1200/JCO.2015.62.3488.
       Full Text  Link to Item
    • Lyman, Gary H., David C. Dale, Jason C. Legg, Esteban Abella, Phuong Khanh Morrow, Sadie Whittaker, and Jeffrey Crawford. “Assessing patients' risk of febrile neutropenia: is there a correlation between physician-assessed risk and model-predicted risk?.” Cancer Medicine 4, no. 8 (August 2015): 1153–60. https://doi.org/10.1002/cam4.454.
       Full Text
    • Lyman, G. H., M. Reiner, P. K. Morrow, and J. Crawford. “The effect of filgrastim or pegfilgrastim on survival outcomes of patients with cancer receiving myelosuppressive chemotherapy..” Annals of Oncology : Official Journal of the European Society for Medical Oncology 26, no. 7 (July 2015): 1452–58. https://doi.org/10.1093/annonc/mdv174.
       Full Text
    • Ready, Neal E., Herbert H. Pang, Lin Gu, Gregory A. Otterson, Sachdev P. Thomas, Antonius A. Miller, Maria Baggstrom, et al. “Chemotherapy With or Without Maintenance Sunitinib for Untreated Extensive-Stage Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase II Study-CALGB 30504 (Alliance)..” J Clin Oncol 33, no. 15 (May 20, 2015): 1660–65. https://doi.org/10.1200/JCO.2014.57.3105.
       Full Text  Link to Item
    • Havrilesky, Laura J., Maureen Reiner, Phuong Khanh Morrow, Holly Watson, and Jeffrey Crawford. “A review of relative dose intensity and survival in patients with metastatic solid tumors..” Critical Reviews in Oncology/Hematology 93, no. 3 (March 2015): 203–10. https://doi.org/10.1016/j.critrevonc.2014.10.006.
       Full Text
    • Pepek, J. M., L. B. Marks, M. F. Berry, N. E. Ready, N. G. Gee, R. E. Coleman, T. A. D’Amico, J. Crawford, and C. R. Kelsey. “Accuracy of positron emission tomography in identifying hilar (N1) lymph node involvement in non-small cell lung cancer: Implications for stereotactic body radiation therapy.” Practical Radiation Oncology 5, no. 2 (March 1, 2015): 79–84. https://doi.org/10.1016/j.prro.2014.05.002.
       Full Text
    • Pepek, Joseph M., Lawrence B. Marks, Mark F. Berry, Neal E. Ready, Nathan G. Gee, R Edward Coleman, Thomas A. D’Amico, Jeffrey Crawford, and Chris R. Kelsey. “Accuracy of positron emission tomography in identifying hilar (N1) lymph node involvement in non-small cell lung cancer: Implications for stereotactic body radiation therapy..” Practical Radiation Oncology 5, no. 2 (March 2015): 79–84. https://doi.org/10.1016/j.prro.2014.05.002.
       Full Text
    • Culakova, Eva, Marek S. Poniewierski, Debra A. Wolff, David C. Dale, Jeffrey Crawford, and Gary H. Lyman. “The impact of chemotherapy dose intensity and supportive care on the risk of febrile neutropenia in patients with early stage breast cancer: a prospective cohort study..” Springerplus 4 (January 2015). https://doi.org/10.1186/s40064-015-1165-6.
       Full Text
    • Havrilesky, L. J., M. Reiner, P. K. Morrow, H. Watson, and J. Crawford. “A review of relative dose intensity and survival in patients with metastatic solid tumors.” Critical Reviews in Oncology/Hematology 93, no. 3 (January 1, 2015): 203–10. https://doi.org/10.1016/j.critrevonc.2014.10.006.
       Full Text
    • Culakova, Eva, Marek S. Poniewierski, Jeffrey Crawford, David C. Dale, and Gary H. Lyman. “Impact of Comorbidities on Length of Stay and Mortality in Hospitalized Patients with Cancer and Febrile Neutropenia.” Blood 124, no. 21 (December 6, 2014).
       Link to Item
    • Xu, Hairong, James A. Kaye, Catherine W. Saltus, Jeffrey Crawford, Eduard Gasal, and Lawrence T. Goodnough. “Blood utilization and hemoglobin levels in cancer patients after label and coverage changes for erythropoiesis-stimulating agents..” Expert Review of Hematology 7, no. 5 (October 2014): 617–33. https://doi.org/10.1586/17474086.2014.943730.
       Full Text
    • Stevenson, Marvaretta, Jared Christensen, Debra Shoemaker, Traci Foster, William T. Barry, Betty C. Tong, Momen Wahidi, et al. “Tumor acquisition for biomarker research in lung cancer..” Cancer Investigation 32, no. 6 (July 2014): 291–98. https://doi.org/10.3109/07357907.2014.911880.
       Full Text
    • Crawford, Jeffrey, and George M. Rodgers. “Treatment strategies for myeloid growth factors and intravenous iron: when, what, and how?.” Journal of the National Comprehensive Cancer Network : Jnccn 12, no. 5 Suppl (May 2014): 821–24. https://doi.org/10.6004/jnccn.2014.0198.
       Full Text
    • Culakova, Eva, Ramya Thota, Marek S. Poniewierski, Nicole M. Kuderer, Adane F. Wogu, David C. Dale, Jeffrey Crawford, and Gary H. Lyman. “Patterns of chemotherapy-associated toxicity and supportive care in US oncology practice: a nationwide prospective cohort study..” Cancer Medicine 3, no. 2 (April 2014): 434–44. https://doi.org/10.1002/cam4.200.
       Full Text
    • Arlen, M., J. Crawford, G. Coppa, O. Saric, J. Bandovic, A. Doubakovski, J. Sullivan, et al. “The cause and prevention of anastomotic recurrence following colectomy: An immunohistochemical approach for detecting transforming colonocytes.” Journal of Cancer 5, no. 9 (January 1, 2014): 784–89. https://doi.org/10.7150/jca.9485.
       Full Text
    • Crawford, Jeffrey, Paul Swanson, Paul Schwarzenberger, Alan Sandler, Diane Prager, Kathy Zhang, Daniel J. Freeman, Carol W. Johnson, Kartik Krishnan, and David Johnson. “A phase 2 randomized trial of paclitaxel and carboplatin with or without panitumumab for first-line treatment of advanced non-small-cell lung cancer..” Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer 8, no. 12 (December 2013): 1510–18. https://doi.org/10.1097/jto.0b013e3182a7d1da.
       Full Text
    • Salama, J. K., H. Pang, J. A. Bogart, A. W. Blackstock, J. J. Urbanic, L. Hodgson, J. Crawford, and E. E. Vokes. “Predictors of pulmonary toxicity in limited stage small cell lung cancer patients treated with induction chemotherapy followed by concurrent platinum-based chemotherapy and 70Gy daily radiotherapy: CALGB 30904.” Lung Cancer 82, no. 3 (December 1, 2013): 436–40. https://doi.org/10.1016/j.lungcan.2013.10.001.
       Full Text
    • Salama, Joseph K., Herbert Pang, Jeffrey A. Bogart, A William Blackstock, James J. Urbanic, Lydia Hogson, Jeffrey Crawford, and Everett E. Vokes. “Predictors of pulmonary toxicity in limited stage small cell lung cancer patients treated with induction chemotherapy followed by concurrent platinum-based chemotherapy and 70 Gy daily radiotherapy: CALGB 30904..” Lung Cancer 82, no. 3 (December 2013): 436–40.
       Link to Item
    • Ramalingam, S., J. Crawford, A. Chang, C. Manegold, R. Perez-Soler, J. -. Y. Douillard, N. Thatcher, et al. “Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial)..” Annals of Oncology : Official Journal of the European Society for Medical Oncology 24, no. 11 (November 2013): 2875–80. https://doi.org/10.1093/annonc/mdt371.
       Full Text
    • Crawford, Jeffrey, James Armitage, Lodovico Balducci, Pamela Sue Becker, Douglas W. Blayney, Spero R. Cataland, Mark L. Heaney, et al. “Myeloid growth factors..” Journal of the National Comprehensive Cancer Network : Jnccn 11, no. 10 (October 2013): 1266–90. https://doi.org/10.6004/jnccn.2013.0148.
       Full Text
    • Crawford, Jeffrey. “Moving forward with myeloid growth factors..” Journal of the National Comprehensive Cancer Network : Jnccn 11, no. 10 (October 2013): 1181–82. https://doi.org/10.6004/jnccn.2013.0139.
       Full Text
    • Lyman, G. H., D. C. Dale, E. Culakova, M. S. Poniewierski, D. A. Wolff, N. M. Kuderer, M. Huang, and J. Crawford. “The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials..” Annals of Oncology : Official Journal of the European Society for Medical Oncology 24, no. 10 (October 2013): 2475–84. https://doi.org/10.1093/annonc/mdt226.
       Full Text
    • Shayne, Michelle, Eva Culakova, Marek S. Poniewierski, David C. Dale, Jeffrey Crawford, Adane F. Wogu, and Gary H. Lyman. “Risk factors for in-hospital mortality and prolonged length of stay in older patients with solid tumor malignancies..” Journal of Geriatric Oncology 4, no. 4 (October 2013): 310–18. https://doi.org/10.1016/j.jgo.2013.05.005.
       Full Text
    • Crawford, Jeffrey. “Prevention and treatment of chemotherapy-induced neutropenia..” Clinical Advances in Hematology & Oncology : H&O 11, no. 8 (August 2013): 514–17.
    • Salama, Joseph K., Lydia Hodgson, Herbert Pang, James J. Urbanic, A William Blackstock, Steven E. Schild, Jeffrey Crawford, Jeffrey A. Bogart, Everett E. Vokes, and Everett E. Cancer and Leukemia Group B. “A pooled analysis of limited-stage small-cell lung cancer patients treated with induction chemotherapy followed by concurrent platinum-based chemotherapy and 70 Gy daily radiotherapy: CALGB 30904..” J Thorac Oncol 8, no. 8 (August 2013): 1043–49. https://doi.org/10.1097/JTO.0b013e318293d8a4.
       Full Text  Link to Item
    • Lyman, Gary H., David C. Dale, Dianne Tomita, Sadie Whittaker, and Jeffrey Crawford. “A retrospective evaluation of chemotherapy dose intensity and supportive care for early-stage breast cancer in a curative setting..” Breast Cancer Research and Treatment 139, no. 3 (June 16, 2013): 863–72. https://doi.org/10.1007/s10549-013-2582-2.
       Full Text
    • Mauguen, Audrey, Jean-Pierre Pignon, Sarah Burdett, Caroline Domerg, David Fisher, Rebecca Paulus, Samithra J. Mandrekar, et al. “Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data..” Lancet Oncol 14, no. 7 (June 2013): 619–26. https://doi.org/10.1016/S1470-2045(13)70158-X.
       Full Text  Link to Item
    • Hanna, Rabbie K., Marek S. Poniewierski, Robin A. Laskey, Micael A. Lopez, Aaron Shafer, Linda Van Le, Jeffrey Crawford, et al. “Predictors of reduced relative dose intensity and its relationship to mortality in women receiving multi-agent chemotherapy for epithelial ovarian cancer..” Gynecologic Oncology 129, no. 1 (April 2013): 74–80. https://doi.org/10.1016/j.ygyno.2012.12.017.
       Full Text
    • Lyman, G. H., D. C. Dale, D. Tomita, S. Whittaker, and J. Crawford. “A retrospective evaluation of chemotherapy dose intensity and supportive care for early-stage breast cancer in a curative setting.” Breast Cancer Research and Treatment 139, no. 3 (2013): 863–72. https://doi.org/10.1007/s10549-013-2582-2.
       Full Text
    • Mauguen, A., J. P. Pignon, S. Burdett, C. Domerg, D. Fisher, R. Paulus, S. J. Mandrekar, et al. “Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: A re-analysis of meta-analyses of individual patients' data.” The Lancet Oncology 14, no. 7 (2013): 619–26. https://doi.org/10.1016/S1470-2045(13)70158-X.
       Full Text
    • Salama, J. K., L. Hodgson, H. Pang, J. J. Urbanic, A. W. Blackstock, S. E. Schild, J. Crawford, J. A. Bogart, and E. E. Vokes. “A pooled analysis of limited-stage small-cell lung cancer patients treated with induction chemotherapy followed by concurrent platinum-based chemotherapy and 70 Gy daily radiotherapy: CALGB 30904.” Journal of Thoracic Oncology 8, no. 8 (2013): 1043–49. https://doi.org/10.1097/JTO.0b013e318293d8a4.
       Full Text
    • Shayne, M., E. Culakova, M. S. Poniewierski, D. C. Dale, J. Crawford, A. F. Wogu, and G. H. Lyman. “Risk factors for in-hospital mortality and prolonged length of stay in older patients with solid tumor malignancies.” Journal of Geriatric Oncology 4, no. 4 (2013): 310–18. https://doi.org/10.1016/j.jgo.2013.05.005.
       Full Text
    • Jänne, Pasi A., Xiaofei Wang, Mark A. Socinski, Jeffrey Crawford, Thomas E. Stinchcombe, Lin Gu, Marzia Capelletti, et al. “Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial..” J Clin Oncol 30, no. 17 (June 10, 2012): 2063–69. https://doi.org/10.1200/JCO.2011.40.1315.
       Full Text  Link to Item
    • Vansteenkiste, Johan, John Glaspy, David Henry, Heinz Ludwig, Robert Pirker, Dianne Tomita, Helen Collins, and Jeffrey Crawford. “Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: study-level and patient-level meta-analyses..” Lung Cancer (Amsterdam, Netherlands) 76, no. 3 (June 2012): 478–85. https://doi.org/10.1016/j.lungcan.2011.12.015.
       Full Text
    • Brodowicz, T., T. Ciuleanu, J. Crawford, M. Filipits, J. R. Fischer, V. Georgoulias, C. Gridelli, et al. “Third CECOG consensus on the systemic treatment of non-small-cell lung cancer..” Annals of Oncology : Official Journal of the European Society for Medical Oncology 23, no. 5 (May 2012): 1223–29. https://doi.org/10.1093/annonc/mdr381.
       Full Text
    • Gaspar, Laurie E., Erica J. McNamara, E Greer Gay, Joe B. Putnam, Jeffrey Crawford, Roy S. Herbst, and James A. Bonner. “Small-cell lung cancer: prognostic factors and changing treatment over 15 years..” Clinical Lung Cancer 13, no. 2 (March 2012): 115–22. https://doi.org/10.1016/j.cllc.2011.05.008.
       Full Text
    • Chan, Arlene, Shailendra Verma, Sibylle Loibl, Jeffrey Crawford, Mi Rim Choi, Lyndah Dreiling, and Ted Vandenberg. “Reporting of myelotoxicity associated with emerging regimens for the treatment of selected solid tumors..” Critical Reviews in Oncology/Hematology 81, no. 2 (February 2012): 136–50. https://doi.org/10.1016/j.critrevonc.2011.03.003.
       Full Text
    • Salama, Joseph K., Thomas E. Stinchcombe, Lin Gu, Xiaofei Wang, Karen Morano, Jeffrey A. Bogart, Jeffrey C. Crawford, et al. “Pulmonary toxicity in Stage III non-small cell lung cancer patients treated with high-dose (74 Gy) 3-dimensional conformal thoracic radiotherapy and concurrent chemotherapy following induction chemotherapy: a secondary analysis of Cancer and Leukemia Group B (CALGB) trial 30105..” Int J Radiat Oncol Biol Phys 81, no. 4 (November 15, 2011): e269–74. https://doi.org/10.1016/j.ijrobp.2011.01.056.
       Full Text  Link to Item
    • Zeliadt, Steven B., Nishant K. Sekaran, Elaine Y. Hu, Christopher C. Slatore, David H. Au, Leah Backhus, Daniel Y. Wu, Jeffrey Crawford, Gary H. Lyman, and David C. Dale. “Comparison of demographic characteristics, surgical resection patterns, and survival outcomes for veterans and nonveterans with non-small cell lung cancer in the Pacific Northwest..” Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer 6, no. 10 (October 2011): 1726–32. https://doi.org/10.1097/jto.0b013e31822ada77.
       Full Text
    • Crawford, Jeffrey, Jeffrey Allen, James Armitage, Douglas W. Blayney, Spero R. Cataland, Mark L. Heaney, Sally Htoy, et al. “Myeloid growth factors..” Journal of the National Comprehensive Cancer Network : Jnccn 9, no. 8 (August 2011): 914–32. https://doi.org/10.6004/jnccn.2011.0075.
       Full Text
    • Lyman, Gary H., Nicole M. Kuderer, Jeffrey Crawford, Debra A. Wolff, Eva Culakova, Marek S. Poniewierski, and David C. Dale. “Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy..” Cancer 117, no. 9 (May 2011): 1917–27. https://doi.org/10.1002/cncr.25691.
       Full Text
    • Krug, Lee M., Jeffrey Crawford, David S. Ettinger, Geoffrey I. Shapiro, David Spigel, Tony Reiman, Jennifer S. Temel, et al. “Phase II multicenter trial of voreloxin as second-line therapy in chemotherapy-sensitive or refractory small cell lung cancer..” Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer 6, no. 2 (February 2011): 384–86. https://doi.org/10.1097/jto.0b013e318200e509.
       Full Text
    • Kuderer, N. M., D. C. Dale, J. Crawford, and G. H. Lyman. “Reply to N. Lathia et al.” Journal of Clinical Oncology 28, no. 36 (December 20, 2010). https://doi.org/10.1200/JCO.2010.30.5607.
       Full Text
    • Dubey, Sarita, Pasi A. Jänne, Lee Krug, Herbert Pang, Xiaofei Wang, Robin Heinze, Colleen Watt, et al. “A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307..” Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer 5, no. 10 (October 2010): 1655–61. https://doi.org/10.1097/JTO.0b013e3181ec18db.
       Full Text
    • Lyman, Gary H., David C. Dale, Debra A. Wolff, Eva Culakova, Marek S. Poniewierski, Nicole M. Kuderer, and Jeffrey Crawford. “Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 28, no. 17 (June 2010): 2914–24. https://doi.org/10.1200/jco.2009.25.8723.
       Full Text
    • Aapro, Matti, Jeffrey Crawford, and Didier Kamioner. “Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now?.” Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer 18, no. 5 (May 2010): 529–41. https://doi.org/10.1007/s00520-010-0816-y.
       Full Text
    • Crawford, J., C. Caserta, F. Roila, and F. ESMO Guidelines Working Group. “Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications..” Annals of Oncology : Official Journal of the European Society for Medical Oncology 21 Suppl 5 (May 2010): v248–51. https://doi.org/10.1093/annonc/mdq195.
       Full Text
    • Jones, Lee W., Neil D. Eves, William E. Kraus, Anil Potti, Jeffrey Crawford, James A. Blumenthal, Bercedis L. Peterson, and Pamela S. Douglas. “The lung cancer exercise training study: a randomized trial of aerobic training, resistance training, or both in postsurgical lung cancer patients: rationale and design..” Bmc Cancer 10 (April 21, 2010). https://doi.org/10.1186/1471-2407-10-155.
       Full Text  Open Access Copy
    • Mostertz, William, Marvaretta Stevenson, Chaitanya Acharya, Isaac Chan, Kelli Walters, Wisut Lamlertthon, William Barry, Jeffrey Crawford, Joseph Nevins, and Anil Potti. “Age- and sex-specific genomic profiles in non-small cell lung cancer..” Jama 303, no. 6 (February 2010): 535–43. https://doi.org/10.1001/jama.2010.80.
       Full Text
    • Zagar, Timothy M., Susan Blackwell, Jeffrey Crawford, Thomas D’Amico, Jared D. Christensen, Thomas A. Sporn, and Chris R. Kelsey. “Preoperative radiation therapy and chemotherapy for pulmonary blastoma: a case report..” Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer 5, no. 2 (February 2010): 282–83. https://doi.org/10.1097/jto.0b013e3181c420e1.
       Full Text
    • Glaspy, J., J. Crawford, J. Vansteenkiste, D. Henry, S. Rao, P. Bowers, J. A. Berlin, D. Tomita, K. Bridges, and H. Ludwig. “Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes..” British Journal of Cancer 102, no. 2 (January 5, 2010): 301–15. https://doi.org/10.1038/sj.bjc.6605498.
       Full Text
    • Brouwers, M., T. K. Oliver, J. Crawford, P. Ellison, W. K. Evans, A. Gagliardi, J. Lacourciere, et al. “Cancer diagnostic assessment programs: Standards for the organization of care in Ontario.” Current Oncology 16, no. 6 (December 1, 2009): 29–41.
    • Stevenson, Marvaretta, William Mostertz, Chaitanya Acharya, William Kim, Kelli Walters, William Barry, Kristin Higgins, et al. “Characterizing the clinical relevance of an embryonic stem cell phenotype in lung adenocarcinoma..” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 15, no. 24 (December 2009): 7553–61. https://doi.org/10.1158/1078-0432.ccr-09-1939.
       Full Text
    • Shayne, Michelle, Eva Culakova, Debra Wolff, Marek S. Poniewierski, David C. Dale, Jeffrey Crawford, and Gary H. Lyman. “Dose intensity and hematologic toxicity in older breast cancer patients receiving systemic chemotherapy..” Cancer 115, no. 22 (November 2009): 5319–28. https://doi.org/10.1002/cncr.24560.
       Full Text
    • Gerena-Lewis, Margie, Jeffrey Crawford, Philip Bonomi, Ann Marie Maddox, John Hainsworth, David E. McCune, Rakesh Shukla, et al. “A Phase II trial of Denileukin Diftitox in patients with previously treated advanced non-small cell lung cancer..” Am J Clin Oncol 32, no. 3 (June 2009): 269–73. https://doi.org/10.1097/COC.0b013e318187dd40.
       Full Text  Link to Item
    • Ludwig, Heinz, Jeffrey Crawford, Anders Osterborg, Johan Vansteenkiste, David H. Henry, Alex Fleishman, Ken Bridges, and John A. Glaspy. “Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 27, no. 17 (June 2009): 2838–47. https://doi.org/10.1200/jco.2008.19.1130.
       Full Text
    • Crawford, J., C. Caserta, F. Roila, and F. ESMO Guidelines Working Group. “Hematopoietic growth factors: ESMO recommendations for the applications..” Annals of Oncology : Official Journal of the European Society for Medical Oncology 20 Suppl 4 (May 2009): 162–65. https://doi.org/10.1093/annonc/mdp162.
       Full Text
    • Crawford, Jeffrey, James Armitage, Lodovico Balducci, Charles Bennett, Douglas W. Blayney, Spero R. Cataland, David C. Dale, et al. “Myeloid growth factors..” Journal of the National Comprehensive Cancer Network : Jnccn 7, no. 1 (January 2009): 64–83. https://doi.org/10.6004/jnccn.2009.0006.
       Full Text
    • Stephenson, Joe J., Charles Gregory, Howard Burris, Tim Larson, Udit Verma, Allen Cohn, Jeffrey Crawford, et al. “An open-label clinical trial evaluating safety and pharmacokinetics of two dosing schedules of panitumumab in patients with solid tumors..” Clinical Colorectal Cancer 8, no. 1 (January 2009): 29–37. https://doi.org/10.3816/ccc.2009.n.005.
       Full Text
    • Jones, Lee W., Neil D. Eves, Bercedis L. Peterson, Jennifer Garst, Jeffrey Crawford, Miranda J. West, Stephanie Mabe, David Harpole, William E. Kraus, and Pamela S. Douglas. “Safety and feasibility of aerobic training on cardiopulmonary function and quality of life in postsurgical nonsmall cell lung cancer patients: a pilot study..” Cancer 113, no. 12 (December 15, 2008): 3430–39. https://doi.org/10.1002/cncr.23967.
       Full Text  Link to Item
    • Meyer, Jeffrey, Momen Wahidi, Scott Shofer, John Evans, Jeffrey Crawford, and Chris R. Kelsey. “Formation of a bronchoesophageal fistula following concurrent radiation and chemotherapy for lung cancer in the setting of Behçet's disease..” Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer 3, no. 11 (November 2008): 1361–62. https://doi.org/10.1097/jto.0b013e31818b1af2.
       Full Text
    • Greco, F Anthony, Philip Bonomi, Jeffrey Crawford, Karen Kelly, Yun Oh, Wendy Halpern, Larry Lo, Gilles Gallant, and Jerry Klein. “Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer..” Lung Cancer (Amsterdam, Netherlands) 61, no. 1 (July 2008): 82–90. https://doi.org/10.1016/j.lungcan.2007.12.011.
       Full Text
    • Crawford, Jeffrey, David C. Dale, Nicole M. Kuderer, Eva Culakova, Marek S. Poniewierski, Debra Wolff, and Gary H. Lyman. “Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice..” Journal of the National Comprehensive Cancer Network : Jnccn 6, no. 2 (February 2008): 109–18. https://doi.org/10.6004/jnccn.2008.0012.
       Full Text
    • Weiner, Louis M., Arie S. Belldegrun, Jeffrey Crawford, Anthony W. Tolcher, Pamela Lockbaum, Rosalin H. Arends, Lynn Navale, Rafael G. Amado, Gisela Schwab, and Robert A. Figlin. “Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies..” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 14, no. 2 (January 2008): 502–8. https://doi.org/10.1158/1078-0432.ccr-07-1509.
       Full Text
    • Shayne, Michelle, Eva Culakova, Marek S. Poniewierski, Debra Wolff, David C. Dale, Jeffrey Crawford, and Gary H. Lyman. “Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy..” Cancer 110, no. 7 (October 2007): 1611–20. https://doi.org/10.1002/cncr.22939.
       Full Text
    • Crawford, Jeffrey. “Hitting our stride..” Supportive Cancer Therapy 4, no. 4 (September 2007): 178–79. https://doi.org/10.3816/sct.2007.n.012.
       Full Text
    • Kuderer, Nicole M., David C. Dale, Jeffrey Crawford, and Gary H. Lyman. “Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review..” J Clin Oncol 25, no. 21 (July 20, 2007): 3158–67. https://doi.org/10.1200/JCO.2006.08.8823.
       Full Text  Link to Item
    • Griggs, Jennifer J., Eva Culakova, Melony E. S. Sorbero, Marek S. Poniewierski, Debra A. Wolff, Jeffrey Crawford, David C. Dale, and Gary H. Lyman. “Social and racial differences in selection of breast cancer adjuvant chemotherapy regimens..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 25, no. 18 (June 2007): 2522–27. https://doi.org/10.1200/jco.2006.10.2749.
       Full Text
    • Riedel, Richard F., Carolyn Andrews, Jennifer Garst, Frank Dunphy, James E. Herndon, Susan Blackwell, Sally Barbour, and Jeffrey Crawford. “A phase II trial of carboplatin/vinorelbine with pegfilgrastim support for the treatment of patients with advanced non-small cell lung cancer..” Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer 2, no. 6 (June 2007): 520–25. https://doi.org/10.1097/jto.0b013e318060107c.
       Full Text
    • Crawford, Jeffrey. “May day..” Supportive Cancer Therapy 4, no. 3 (May 2007): 135–36. https://doi.org/10.3816/sct.2007.n.007.
       Full Text
    • Crawford, Jeffrey. “Update on neutropenia and myeloid growth factors..” The Journal of Supportive Oncology 5, no. 4 Suppl 2 (April 2007): 27–46.
    • Crawford, Jeffrey, Francisco Robert, Michael C. Perry, Chandra Belani, Denise Williams, and Denise Anemia Prevention in NSCLC Group. “A randomized trial comparing immediate versus delayed treatment of anemia with once-weekly epoetin alfa in patients with non-small cell lung cancer scheduled to receive first-line chemotherapy..” Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer 2, no. 3 (March 2007): 210–20. https://doi.org/10.1097/jto.0b013e318031cd9a.
       Full Text
    • Crawford, Jeffrey. “Erythropoietin: high profile, high scrutiny..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 25, no. 9 (March 2007): 1021–23. https://doi.org/10.1200/jco.2006.08.8153.
       Full Text
    • Crawford, Jeffrey, Betsy Althaus, James Armitage, Lodovico Balducci, Charles Bennett, Douglas W. Blayney, Spero R. Cataland, et al. “Myeloid growth factors. Clinical practice guidelines in oncology..” Journal of the National Comprehensive Cancer Network : Jnccn 5, no. 2 (February 2007): 188–202. https://doi.org/10.6004/jnccn.2007.0019.
       Full Text
    • “Controlling symptoms in elderly lung cancer patients..” The Journal of Supportive Oncology 5, no. 2 (February 2007): 78–79.
    • Cosler, Leon E., Adi Eldar-Lissai, Eva Culakova, Nicole M. Kuderer, David Dale, Jeffrey Crawford, and Gary H. Lyman. “Therapeutic use of granulocyte colony-stimulating factors for established febrile neutropenia: effect on costs from a hospital perspective..” Pharmacoeconomics 25, no. 4 (2007): 343–51. https://doi.org/10.2165/00019053-200725040-00006.
       Full Text  Link to Item
    • Crawford, Jeffrey. “Cancer management in the era of targeted agents..” Supportive Cancer Therapy 4, no. 2 (January 2007). https://doi.org/10.3816/sct.2007.n.001.
       Full Text
    • Griggs, Jennifer J., Eva Culakova, Melony E. S. Sorbero, Michelle van Ryn, Marek S. Poniewierski, Debra A. Wolff, Jeffrey Crawford, David C. Dale, and Gary H. Lyman. “Effect of patient socioeconomic status and body mass index on the quality of breast cancer adjuvant chemotherapy..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 25, no. 3 (January 2007): 277–84. https://doi.org/10.1200/jco.2006.08.3063.
       Full Text
    • Reddy, G. K., L. Shivakumar, S. Muneer, and J. Crawford. “A phase II study of eltrombopag in the treatment of thrombocytopenia in patients with relapsed/refractory idiopathic thrombocytopenic purpura.” Supportive Cancer Therapy 4, no. 2 (January 1, 2007): 73–74.
    • Reddy, G. K., L. Shivakumar, S. Muneer, and J. Crawford. “Long-term analysis of the safety and tolerability of the oral iron chelator deferasirox in patients with transfusional iron overload.” Supportive Cancer Therapy 4, no. 2 (January 1, 2007): 75–77.
    • Reddy, G. K., L. Shivakumar, S. Muneer, and J. Crawford. “Preliminary results of a phase II dose-finding study of subcutaneous Hematide™ in patients with cancer receiving chemotherapy.” Supportive Cancer Therapy 4, no. 2 (January 1, 2007): 74–75.
    • Reddy, G. K., L. Shivakumar, S. Muneer, and J. Crawford. “Long-term effects of the novel thrombopoietic agent AMG-531 in patients with immune thrombocytopenic purpura.” Supportive Cancer Therapy 4, no. 2 (January 1, 2007): 72–73.
    • Riedel, Richard F., Jeffrey Crawford, Frank Dunphy, James E. Herndon, Jennifer Garst, and Michael J. Kelley. “Phase II study of carboplatin, irinotecan, and thalidomide combination in patients with extensive stage small-cell lung cancer..” Lung Cancer (Amsterdam, Netherlands) 54, no. 3 (December 2006): 431–32. https://doi.org/10.1016/j.lungcan.2006.08.008.
       Full Text
    • Shayne, Michelle, Jeffrey Crawford, David C. Dale, Eva Culakova, Gary H. Lyman, and Gary H. ANC Study Group. “Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy..” Breast Cancer Research and Treatment 100, no. 3 (December 2006): 255–62. https://doi.org/10.1007/s10549-006-9254-4.
       Full Text
    • Fanucchi, Michael P., Frank V. Fossella, Robert Belt, Ronald Natale, Panos Fidias, David P. Carbone, Ramaswamy Govindan, et al. “Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 24, no. 31 (November 2006): 5025–33. https://doi.org/10.1200/jco.2006.06.1853.
       Full Text
    • Aapro, M. S., D. A. Cameron, R. Pettengell, J. Bohlius, J. Crawford, M. Ellis, N. Kearney, et al. “EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours..” European Journal of Cancer (Oxford, England : 1990) 42, no. 15 (October 2006): 2433–53. https://doi.org/10.1016/j.ejca.2006.05.002.
       Full Text
    • Anscher, Mitchell S., Jennifer Garst, Lawrence B. Marks, Nicole Larrier, Frank Dunphy, James E. Herndon, Robert Clough, et al. “Assessing the ability of the antiangiogenic and anticytokine agent thalidomide to modulate radiation-induced lung injury..” Int J Radiat Oncol Biol Phys 66, no. 2 (October 1, 2006): 477–82. https://doi.org/10.1016/j.ijrobp.2006.05.031.
       Full Text  Link to Item
    • Crawford, Jeffrey. “Disease management and patient-reported outcomes..” Supportive Cancer Therapy 4, no. 1 (October 2006). https://doi.org/10.3816/sct.2006.n.025.
       Full Text
    • Crawford, Jeffrey, Paris A. Kosmidis, Fred R. Hirsch, and Corey J. Langer. “Targeting anemia in patients with lung cancer..” Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer 1, no. 7 (September 2006): 716–25. https://doi.org/10.1016/s1556-0864(15)30388-9.
       Full Text
    • Crawford, Jeffrey. “Erythropoiesis-stimulating protein support and survival..” Oncology (Williston Park, N.Y.) 20, no. 8 Suppl 6 (July 2006): 39–43.
    • Johnson, Bruce E., Jeffrey Crawford, Robert J. Downey, David S. Ettinger, Frank Fossella, John C. Grecula, Thierry Jahan, et al. “Small cell lung cancer clinical practice guidelines in oncology..” Journal of the National Comprehensive Cancer Network : Jnccn 4, no. 6 (July 2006): 602–22. https://doi.org/10.6004/jnccn.2006.0050.
       Full Text
    • Smith, Thomas J., James Khatcheressian, Gary H. Lyman, Howard Ozer, James O. Armitage, Lodovico Balducci, Charles L. Bennett, et al. “2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline..” J Clin Oncol 24, no. 19 (July 1, 2006): 3187–3205. https://doi.org/10.1200/JCO.2006.06.4451.
       Full Text  Link to Item
    • Kuderer, Nicole M., David C. Dale, Jeffrey Crawford, Leon E. Cosler, and Gary H. Lyman. “Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients..” Cancer 106, no. 10 (May 2006): 2258–66. https://doi.org/10.1002/cncr.21847.
       Full Text
    • Crawford, Jeffrey. “Risk assessment and guidelines for first-cycle colony-stimulating factor use in the management of chemotherapy-induced neutropenia..” Oncology (Williston Park, N.Y.) 20, no. 5 Suppl 4 (April 2006): 22–28.
    • Crawford, Jeffrey. “Colony-stimulating factor use in the context of refined risk and benefit assessments..” Oncology (Williston Park, N.Y.) 20, no. 5 Suppl 4 (April 2006): 9–10.
    • Crawford, Jeffrey. “Becoming a supportive cancer therapy generalist..” Supportive Cancer Therapy 3, no. 3 (April 2006). https://doi.org/10.3816/sct.2006.n.009.
       Full Text
    • Daniel, Davey, and Jeffrey Crawford. “Myelotoxicity from chemotherapy..” Seminars in Oncology 33, no. 1 (February 2006): 74–85. https://doi.org/10.1053/j.seminoncol.2005.11.003.
       Full Text
    • Crawford, Jeffrey. “Integrating support into cancer therapy..” Supportive Cancer Therapy 3, no. 2 (January 2006): 71–72. https://doi.org/10.3816/sct.2006.n.001.
       Full Text
    • Garst, Jennifer, James E. Herndon, Timothy Shafman, Lara Campagna, Susan Blackwell, Karen Padilla, Toni Bjurstrom, et al. “A phase I study of dose-dense topotecan given upfront to standard therapy in patients with small cell lung cancer..” Clinical Drug Investigation 26, no. 5 (January 2006): 257–66. https://doi.org/10.2165/00044011-200626050-00003.
       Full Text
    • Reddy, G. K., J. Crawford, and V. K. Jain. “The role of Plerixafor (AMD3100) in mobilizing hematopoietic progenitor cells in patients with hematologic malignancies.” Supportive Cancer Therapy 3, no. 2 (January 1, 2006): 73–76. https://doi.org/10.1016/S1543-2912(13)60060-0.
       Full Text
    • Daniel, Davey B., Jeffrey Crawford, and Jeffrey National Comprehensive Cancer Network. “Shifting guidelines for myeloid growth factors: applications in cancer chemotherapy..” Current Hematology Reports 4, no. 6 (November 2005): 441–45.
    • Garst, Jennifer, Richard Buller, Stephen Lane, and Jeffrey Crawford. “Topotecan in the treatment of elderly patients with relapsed small-cell lung cancer..” Clinical Lung Cancer 7, no. 3 (November 2005): 190–96. https://doi.org/10.3816/clc.2005.n.035.
       Full Text
    • Wolff, D., E. Culakova, M. S. Poniewierski, G. H. Lyman, D. C. Dale, and J. Crawford. “Predictors of chemotherapy-induced neutropenia and its complications: Results from a prospective nationwide registry.” Journal of Supportive Oncology 3, no. 6 SUPPL. 4 (November 1, 2005): 24–25.
    • Zielinski, C. C., M. Krainer, R. Pirker, S. Tomek, S. Zöchbauer-Müller, T. Beinert, J. Crawford, et al. “Consensus on medical treatment of non-small-cell lung cancer - Update 2004.” Lung Cancer 50, no. 1 (October 1, 2005): 129–37. https://doi.org/10.1016/j.lungcan.2005.05.014.
       Full Text
    • Crawford, Jeffrey, Betsy Althaus, James Armitage, Douglas W. Blayney, Spero Cataland, David C. Dale, George D. Demetri, et al. “Myeloid growth factors clinical practice guidelines in oncology..” Journal of the National Comprehensive Cancer Network : Jnccn 3, no. 4 (July 2005): 540–55. https://doi.org/10.6004/jnccn.2005.0030.
       Full Text
    • Lamont, Elizabeth B., James E. Herndon, Jane C. Weeks, I Craig Henderson, Rogerio Lilenbaum, Richard L. Schilsky, and Nicholas A. Christakis. “Criterion validity of Medicare chemotherapy claims in Cancer and Leukemia Group B breast and lung cancer trial participants..” Journal of the National Cancer Institute 97, no. 14 (July 2005): 1080–83. https://doi.org/10.1093/jnci/dji189.
       Full Text
    • Vokes, Everett E., Jeffrey Crawford, Jeffrey Bogart, Mark A. Socinski, Gerald Clamon, and Mark R. Green. “Concurrent chemoradiotherapy for unresectable stage III non-small cell lung cancer..” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 11, no. 13 Pt 2 (July 2005): 5045s-5050s. https://doi.org/10.1158/1078-0432.ccr-05-9008.
       Full Text
    • Gaspar, Laurie E., E Greer Gay, Jeffrey Crawford, Joe B. Putnam, Roy S. Herbst, and James A. Bonner. “Limited-stage small-cell lung cancer (stages I-III): observations from the National Cancer Data Base..” Clinical Lung Cancer 6, no. 6 (May 2005): 355–60. https://doi.org/10.3816/clc.2005.n.015.
       Full Text
    • Leighl, Natasha B., Luis Paz-Ares, Jean-Yves Douillard, Christian Peschel, Andrew Arnold, Alain Depierre, Armando Santoro, et al. “Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 23, no. 12 (April 2005): 2831–39. https://doi.org/10.1200/jco.2005.04.044.
       Full Text
    • Crawford, J., D. Wolff, E. Culakova, M. S. Poniewierski, C. Selby, D. Dale, and G. H. Lyman. “First-cycle risk of severe and febrile neutropenia in cancer patients receiving systemic chemotherapy: Results from a prospective nationwide study.” Journal of Supportive Oncology 3, no. 2 SUPPL. 1 (March 1, 2005): 52–53.
    • Wolff, D. A., J. Crawford, D. C. Dale, M. S. Poniewierski, and G. H. Lyman. “Risk of neutropenic complications based on a prospective nationwide registry of cancer patients initiating systemic chemotherapy.” Journal of Supportive Oncology 3, no. 2 SUPPL. 1 (March 1, 2005): 56–57.
    • Cosler, Leon E., Visaharan Sivasubramaniam, Olayemi Agboola, Jeffrey Crawford, David Dale, and Gary H. Lyman. “Effect of outpatient treatment of febrile neutropenia on the risk threshold for the use of CSF in patients with cancer treated with chemotherapy..” Value in Health : The Journal of the International Society for Pharmacoeconomics and Outcomes Research 8, no. 1 (January 2005): 47–52. https://doi.org/10.1111/j.1524-4733.2005.03099.x.
       Full Text
    • Miller, Keith L., Timothy D. Shafman, Mitchell S. Anscher, Su-Min Zhou, Robert W. Clough, Jennifer L. Garst, Jeffrey Crawford, et al. “Bronchial stenosis: an underreported complication of high-dose external beam radiotherapy for lung cancer?.” Int J Radiat Oncol Biol Phys 61, no. 1 (January 1, 2005): 64–69. https://doi.org/10.1016/j.ijrobp.2004.02.066.
       Full Text  Link to Item
    • Crawford, Jeffrey. “The importance of chemotherapy dose intensity in lung cancer..” Seminars in Oncology 31, no. 6 Suppl 15 (December 2004): 25–31. https://doi.org/10.1053/j.seminoncol.2004.11.025.
       Full Text
    • Lyman, Gary H., David C. Dale, Jonathan Friedberg, Jeffrey Crawford, and Richard I. Fisher. “Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 22, no. 21 (November 2004): 4302–11. https://doi.org/10.1200/jco.2004.03.213.
       Full Text
    • Marks, Lawrence B., Jennifer Garst, Mark A. Socinski, Gregory Sibley, A William Blackstock, James E. Herndon, Sunmin Zhou, et al. “Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: report of a prospective phase I dose escalation trial from the Carolina Conformal Therapy Consortium..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 22, no. 21 (November 2004): 4329–40. https://doi.org/10.1200/jco.2004.02.165.
       Full Text
    • Socinski, M. A., C. Zhang, J. E. Herndon, R. O. Dillman, G. Clamon, E. Vokes, W. Akerley, et al. “Combined modality trials of the Cancer and Leukemia Group B in stage III non-small-cell lung cancer: analysis of factors influencing survival and toxicity..” Annals of Oncology : Official Journal of the European Society for Medical Oncology 15, no. 7 (July 2004): 1033–41. https://doi.org/10.1093/annonc/mdh282.
       Full Text
    • Crawford, J., D. C. Dale, and G. H. Lyman. “Erratum: Chemotherapy-induced neutropenia: Risks, consequences, and new directions for its management (Cancer (2004) 100 (228-237)).” Cancer 100, no. 9 (May 1, 2004): 1993–94. https://doi.org/10.1002/cncr.20218.
       Full Text
    • Crawford, Jeffrey. “Improving the management of chemotherapy-induced neutropenia..” The Journal of Supportive Oncology 2, no. 2 Suppl 2 (March 2004): 36–39.
    • Foon, Kenneth A., Xiao-Dong Yang, Louis M. Weiner, Arie S. Belldegrun, Robert A. Figlin, Jeffrey Crawford, Eric K. Rowinsky, et al. “Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody..” International Journal of Radiation Oncology, Biology, Physics 58, no. 3 (March 2004): 984–90. https://doi.org/10.1016/j.ijrobp.2003.09.098.
       Full Text
    • Rocha Lima, C. M., N. A. Rizvi, C. Zhang, J. E. Herndon, J. Crawford, R. Govindan, G. W. King, M. R. Green, and M. R. Cancer Leukemia Group B. “Randomized phase II trial of gemcitabine plus irinotecan or docetaxel in stage IIIB or stage IV NSCLC..” Ann Oncol 15, no. 3 (March 2004): 410–18. https://doi.org/10.1093/annonc/mdh104.
       Full Text  Link to Item
    • Crawford, Jeffrey, David C. Dale, and Gary H. Lyman. “Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management..” Cancer 100, no. 2 (January 2004): 228–37. https://doi.org/10.1002/cncr.11882.
       Full Text
    • Lyman, Gary H., David C. Dale, and Jeffrey Crawford. “Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 21, no. 24 (December 2003): 4524–31. https://doi.org/10.1200/jco.2003.05.002.
       Full Text
    • Lyman, Gary H., Vicki A. Morrison, David C. Dale, Jeffrey Crawford, David J. Delgado, Moshe Fridman, Moshe OPPS Working Group, and Moshe ANC Study Group. “Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy..” Leukemia & Lymphoma 44, no. 12 (December 2003): 2069–76. https://doi.org/10.1080/1042819031000119262.
       Full Text
    • Paridaens, R., G. H. Lyman, R. Leonard, J. Crawford, A. Bosly, M. Constenla, C. Jackisch, R. Pettengell, and T. Szucs. “Delivering optimal adjuvant chemotherapy in primary breast cancer: The role of rHuG-CSF.” European Journal of Cancer, Supplement 1, no. 9 (November 1, 2003): 1–12. https://doi.org/10.1016/S1359-6349(03)00082-X.
       Full Text
    • Riedel, Richard F., and Jeffrey Crawford. “Small-cell lung cancer: a review of clinical trials..” Seminars in Thoracic and Cardiovascular Surgery 15, no. 4 (October 2003): 448–56. https://doi.org/10.1053/s1043-0679(03)00098-4.
       Full Text
    • Crawford, Jeffrey. “Once-per-cycle pegfilgrastim (Neulasta) for the management of chemotherapy-induced neutropenia..” Seminars in Oncology 30, no. 4 Suppl 13 (August 2003): 24–30. https://doi.org/10.1016/s0093-7754(03)00314-2.
       Full Text
    • Crawford, Jeffrey. “Safety and efficacy of pegfilgrastim in patients receiving myelosuppressive chemotherapy..” Pharmacotherapy 23, no. 8 Pt 2 (August 2003): 15S-19S. https://doi.org/10.1592/phco.23.9.15s.32889.
       Full Text
    • Anscher, Mitchell S., Lawrence B. Marks, Timothy D. Shafman, Robert Clough, Hong Huang, Andrea Tisch, Michael Munley, et al. “Risk of long-term complications after TFG-beta1-guided very-high-dose thoracic radiotherapy..” International Journal of Radiation Oncology, Biology, Physics 56, no. 4 (July 2003): 988–95. https://doi.org/10.1016/s0360-3016(03)00184-6.
       Full Text
    • Dale, David C., Gordon C. McCarter, Jeffrey Crawford, and Gary H. Lyman. “Myelotoxicity and dose intensity of chemotherapy: reporting practices from randomized clinical trials..” Journal of the National Comprehensive Cancer Network : Jnccn 1, no. 3 (July 2003): 440–54.
    • Miller, Keith L., Lawrence B. Marks, Gregory S. Sibley, Robert W. Clough, Jennifer L. Garst, Jeffrey Crawford, and Timothy D. Shafman. “Routine use of approximately 60 Gy once-daily thoracic irradiation for patients with limited-stage small-cell lung cancer..” International Journal of Radiation Oncology, Biology, Physics 56, no. 2 (June 2003): 355–59. https://doi.org/10.1016/s0360-3016(02)04493-0.
       Full Text
    • Crawford, J. “Pegfilgrastim: the promise of pegylation fulfilled..” Ann Oncol 14, no. 1 (January 2003): 6–7. https://doi.org/10.1093/annonc/mdg036.
       Full Text  Link to Item
    • Crawford, Jeffrey. “New targeted therapies for non-small-cell lung cancer: a focus on the epidermal growth factor receptor..” Journal of the National Comprehensive Cancer Network : Jnccn 1 Suppl 1 (January 2003): S78–86.
    • Vlahovic, Gordana, and Jeffrey Crawford. “Activation of tyrosine kinases in cancer..” The Oncologist 8, no. 6 (January 2003): 531–38. https://doi.org/10.1634/theoncologist.8-6-531.
       Full Text
    • Central European Cooperative Oncology Group(CECOG), T. M., T. M. Advisory Committee on Collaboration with Industry in Medical Education of the European School of Oncolofy (ESO), and T. M. Vienna Medical Association. “Consensus on medical treatment of non-small cell lung cancer..” Lung Cancer (Amsterdam, Netherlands) 38 Suppl 3 (December 2002): S3–7. https://doi.org/10.1016/s0169-5002(02)00243-x.
       Full Text
    • Crawford, J. “Pegfilgrastim for the prevention of chemotherapy-induced neutropenic complications, with dosing once per chemotherapy cycle.” Today’S Therapeutic Trends 20, no. 4 (December 1, 2002): 393–418.
    • Crawford, Jeffrey. “Anemia and lung cancer..” Lung Cancer (Amsterdam, Netherlands) 38 Suppl 3 (December 2002): S75–78. https://doi.org/10.1016/s0169-5002(02)00275-1.
       Full Text
    • Crawford, Jeffrey. “Neutrophil growth factors..” Current Hematology Reports 1, no. 2 (November 2002): 95–102.
    • Vokes, Everett E., James E. Herndon, Jeffrey Crawford, Kenneth A. Leopold, Michael C. Perry, Antonius A. Miller, and Mark R. Green. “Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431..” J Clin Oncol 20, no. 20 (October 15, 2002): 4191–98. https://doi.org/10.1200/JCO.2002.03.054.
       Full Text  Link to Item
    • Crawford, Jeffrey. “Recombinant human erythropoietin in cancer-related anemia. Review of clinical evidence..” Oncology (Williston Park, N.Y.) 16, no. 9 Suppl 10 (September 2002): 41–53.
    • Farag, Sherif S., Stephen L. George, Edward J. Lee, Maria Baer, Richard K. Dodge, Brian Becknell, Todd A. Fehniger, et al. “Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420..” Clin Cancer Res 8, no. 9 (September 2002): 2812–19.
       Link to Item
    • Kornblith, Alice B., Margaret Kemeny, Bercedis L. Peterson, Judith Wheeler, Jeffrey Crawford, Nancy Bartlett, Gini Fleming, et al. “Survey of oncologists' perceptions of barriers to accrual of older patients with breast carcinoma to clinical trials..” Cancer 95, no. 5 (September 2002): 989–96. https://doi.org/10.1002/cncr.10792.
       Full Text
    • Crawford, Jeffrey, David Cella, Charles S. Cleeland, Pierre-Yves Cremieux, George D. Demetri, Brenda J. Sarokhan, Mitchell B. Slavin, and John A. Glaspy. “Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy..” Cancer 95, no. 4 (August 2002): 888–95. https://doi.org/10.1002/cncr.10763.
       Full Text
    • Crawford, J. “Clinical benefits of pegylated proteins in oncology..” Cancer Treatment Reviews 28 Suppl A (April 2002): 1–2. https://doi.org/10.1016/s0305-7372(02)80001-9.
       Full Text
    • Crawford, J. “Clinical uses of pegylated pharmaceuticals in oncology..” Cancer Treatment Reviews 28 Suppl A (April 2002): 7–11. https://doi.org/10.1016/s0305-7372(02)80003-2.
       Full Text
    • Crawford, Jeffrey, George D. Demetri, Janice L. Gabrilove, Michael V. Blasi, Brenda J. Sarokhan, and John Glaspy. “Clinical benefits of epoetin alfa therapy in patients with lung cancer..” Clinical Lung Cancer 3, no. 3 (February 2002): 180–90. https://doi.org/10.3816/clc.2002.n.001.
       Full Text
    • Crawford, Jeffrey. “Pegfilgrastim administered once per cycle reduces incidence of chemotherapy-induced neutropenia..” Drugs 62 Suppl 1 (January 2002): 89–98. https://doi.org/10.2165/00003495-200262001-00007.
       Full Text
    • Anscher, M. S., L. B. Marks, T. D. Shafman, R. Clough, H. Huang, A. Tisch, M. Munley, et al. “Using plasma transforming growth factor beta-1 during radiotherapy to select patients for dose escalation..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 19, no. 17 (September 2001): 3758–65. https://doi.org/10.1200/jco.2001.19.17.3758.
       Full Text
    • Niell, H. B., M. C. Perry, G. Clamon, J. Crawford, A. A. Miller, J. Herndon, and M. R. Green. “Carboplatin/etoposide/paclitaxel in the treatment of patients with extensive small-cell lung cancer..” Clinical Lung Cancer 2, no. 3 (February 2001): 204–9. https://doi.org/10.3816/clc.2001.n.004.
       Full Text
    • Socinski, M. A., L. B. Marks, J. Garst, G. S. Sibley, W. Blackstock, A. Turrisi, J. Herndon, et al. “Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: a preliminary report of a phase I dose escalation trial from the Carolina Conformal Therapy Consortium..” The Oncologist 6 Suppl 1 (January 2001): 20–24. https://doi.org/10.1634/theoncologist.6-suppl_1-20.
       Full Text
    • Ozer, H., J. O. Armitage, C. L. Bennett, J. Crawford, G. D. Demetri, P. A. Pizzo, C. A. Schiffer, et al. “2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 18, no. 20 (October 2000): 3558–85. https://doi.org/10.1200/jco.2000.18.20.3558.
       Full Text
    • Johnston, E., J. Crawford, S. Blackwell, T. Bjurstrom, P. Lockbaum, L. Roskos, B. B. Yang, et al. “Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 18, no. 13 (July 2000): 2522–28. https://doi.org/10.1200/jco.2000.18.13.2522.
       Full Text
    • Fossella, F. V., R. DeVore, R. N. Kerr, J. Crawford, R. R. Natale, F. Dunphy, L. Kalman, et al. “Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 18, no. 12 (June 2000): 2354–62. https://doi.org/10.1200/jco.2000.18.12.2354.
       Full Text
    • Crawford, J., D. K. Tomita, R. Mazanet, J. Glaspy, and H. Ozer. “Reduction of oral mucositis by filgrastim (r-metHuG-CSF) in patients receiving chemotherapy..” Cytokines, Cellular & Molecular Therapy 5, no. 4 (December 1999): 187–93.
    • Cremieux, P. Y., S. N. Finkelstein, E. R. Berndt, J. Crawford, and M. B. Slavin. “Cost effectiveness, quality-adjusted life-years and supportive care. Recombinant human erythropoietin as a treatment of cancer-associated anaemia..” Pharmacoeconomics 16, no. 5 Pt 1 (November 1999): 459–72. https://doi.org/10.2165/00019053-199916050-00004.
       Full Text
    • DeVore, R. F., D. H. Johnson, J. Crawford, J. Garst, I. W. Dimery, J. Eckardt, S. G. Eckhardt, et al. “Phase II study of irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 17, no. 9 (September 1999): 2710–20. https://doi.org/10.1200/jco.1999.17.9.2710.
       Full Text
    • Crawford, J., M. Foote, and G. Morstyn. “Hematopoietic growth factors in cancer chemotherapy..” Cancer Chemotherapy and Biological Response Modifiers 18 (January 1999): 250–67.
    • Johnston, E. M., and J. Crawford. “Hematopoietic growth factors in the reduction of chemotherapeutic toxicity..” Seminars in Oncology 25, no. 5 (October 1998): 552–61.
    • Devore, R., D. Johnson, J. Crawford, I. Dimery, J. Eckardt, and S. G. Eckhardt. “Irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer..” Oncology (Williston Park, N.Y.) 12, no. 8 Suppl 6 (August 1998): 79–83.
    • Mehdi, S. A., M. C. Perry, J. E. Herndon, J. Crawford, R. Young, and S. L. Graziano. “A study of filgrastim (rG-CSF) priming of etoposide/cisplatin in advanced non-small cell lung cancer..” Journal of Interferon & Cytokine Research : The Official Journal of the International Society for Interferon and Cytokine Research 18, no. 8 (August 1998): 623–27. https://doi.org/10.1089/jir.1998.18.623.
       Full Text
    • Persons, D. A., J. Garst, R. Vollmer, and J. Crawford. “Tumor lysis syndrome and acute renal failure after treatment of non-small-cell lung carcinoma with combination irinotecan and cisplatin..” American Journal of Clinical Oncology 21, no. 4 (August 1998): 426–29. https://doi.org/10.1097/00000421-199808000-00024.
       Full Text
    • Cohen, H. J., J. Crawford, M. K. Rao, C. F. Pieper, and M. S. Currie. “Racial differences in the prevalence of monoclonal gammopathy in a community-based sample of the elderly..” The American Journal of Medicine 104, no. 5 (May 1998): 439–44. https://doi.org/10.1016/s0002-9343(98)00080-1.
       Full Text
    • Crawford, J., and S. Blackwell. “Erythropoietin and the management of anemia in patients with lung cancer.” Cancer Control 5, no. 2 SUPPL. (May 1, 1998): 26–32.
    • Cohen, H. J., J. Crawford, and M. K. Rao. “Erratum: Racial differences in the prevalence of monoclonal gammopathy in a community-based sample of the elderly (The American Journal of Medicine (1998) 104 (439-444)).” American Journal of Medicine 105, no. 4 (January 1, 1998).
    • Crawford, J., J. Garst, and M. A. O’Rourke. “Vinorelbine and Carboplatin in the Treatment of Advanced Non-Small-Cell Lung Cancer.” Oncology 11, no. 10 SUPPL. 11 (December 1, 1997): 44–48.
    • Crawford, J., H. Kreisman, H. Garewal, S. E. Jones, D. Shoemaker, M. R. Pupa, S. Armstrong, D. Tomita, and G. Dziem. “The impact of Filgrastim schedule variation on hematopoietic recovery post-chemotherapy..” Ann Oncol 8, no. 11 (November 1997): 1117–24. https://doi.org/10.1023/a:1008271804151.
       Full Text  Link to Item
    • Niell, H. B., A. A. Miller, G. H. Clamon, M. C. Perry, J. Crawford, and M. R. Green. “A phase II study evaluating the efficacy of carboplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in patients with stage IIIB and IV non-small cell lung cancer and extensive small cell lung cancer.” Seminars in Oncology 24, no. 4 SUPPL.12 (October 22, 1997).
    • Neill, H. B., A. A. Miller, G. H. Clamon, M. C. Perry, J. Crawford, and M. R. Green. “A phase II study evaluating the efficacy of carboplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in patients with stage IIIB and IV non-small cell lung cancer and extensive small cell lung cancer..” Seminars in Oncology 24, no. 4 Suppl 12 (August 1997).
    • Petros, W. P., and J. Crawford. “Safety of concomitant use of granulocyte colony-stimulating factor or granulocyte-macrophage colony-stimulating factor with cytotoxic chemotherapy agents..” Current Opinion in Hematology 4, no. 3 (May 1997): 213–16.
    • Fanucchi, M., J. Glaspy, J. Crawford, J. Garst, R. Figlin, W. Sheridan, D. Menchaca, D. Tomita, H. Ozer, and L. Harker. “Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer..” The New England Journal of Medicine 336, no. 6 (February 1997): 404–9. https://doi.org/10.1056/nejm199702063360603.
       Full Text
    • Luikart, S. D., J. E. Herndon, D. R. Hollis, M. MacDonald, L. H. Maurer, J. Crawford, G. H. Clamon, et al. “Phase I trial of etoposide, carboplatin, and GM-CSF in extensive small-cell lung cancer: a Cancer and Leukemia Group B study (CALGB 8832)..” American Journal of Clinical Oncology 20, no. 1 (February 1997): 24–30. https://doi.org/10.1097/00000421-199702000-00006.
       Full Text
    • Crawford, J., M. O’Rourke, J. H. Schiller, C. H. Spiridonidis, S. Yanovich, H. Ozer, A. Langleben, et al. “Randomized trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV non-small-cell lung cancer..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 14, no. 10 (October 1996): 2774–84. https://doi.org/10.1200/jco.1996.14.10.2774.
       Full Text
    • Graziano, S. L., F. H. Valone, J. E. Herndon, J. Crawford, F. Richards, V. B. Rege, G. Clamon, and M. R. Green. “A randomized phase II study of ifosfamide/mesna/cisplatin plus G-CSF or etoposide/cisplatin plus G-CSF in advanced non-small cell lung cancer: a Cancer and Leukemia Group B study..” Lung Cancer (Amsterdam, Netherlands) 14, no. 2–3 (June 1996): 315–29. https://doi.org/10.1016/0169-5002(96)00556-9.
       Full Text
    • “Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. American Society of Clinical Oncology..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 14, no. 6 (June 1996): 1957–60. https://doi.org/10.1200/jco.1996.14.6.1957.
       Full Text
    • Crawford, J., and E. E. Vokes. “Update on the role of vinorelbine in the treatment of non-small cell lung cancer: Introduction.” Seminars in Oncology 23, no. 2 SUPPL. 5 (May 6, 1996).
    • Crawford, J. “Update: vinorelbine (navelbine) in non-small cell lung cancer..” Seminars in Oncology 23, no. 2 Suppl 5 (April 1996): 2–7.
    • Crawford, J., A. Y. Chang, R. J. Gralla, P. J. Souquet, and E. E. Vokes. “Combination regimens and dose intensification in non-small cell lung cancer: a panel discussion (Part 1)..” Seminars in Oncology 23, no. 2 Suppl 5 (April 1996): 22–24.
    • Crawford, J., D. S. Duch, R. J. Gralla, B. E. Hillner, P. J. Hollen, and E. E. Vokes. “Pharmacoeconomics, quality of life, and combination modalities in non-small cell lung cancer: a panel discussion (Part 2)..” Seminars in Oncology 23, no. 2 Suppl 5 (April 1996): 53–55.
    • Patz, E. F., H. P. McAdams, P. C. Goodman, S. Blackwell, and J. Crawford. “Ambulatory sclerotherapy for malignant pleural effusions..” Radiology 199, no. 1 (April 1996): 133–35. https://doi.org/10.1148/radiology.199.1.8633136.
       Full Text
    • Grichnik, J. M., J. Crawford, F. Jimenez, J. Kurtzberg, M. Buchanan, S. Blackwell, R. E. Clark, and M. G. Hitchcock. “Human recombinant stem-cell factor induces melanocytic hyperplasia in susceptible patients..” Journal of the American Academy of Dermatology 33, no. 4 (October 1995): 577–83. https://doi.org/10.1016/0190-9622(95)91274-6.
       Full Text
    • Crawford, J., and M. George. “The role of hematopoietic growth factors in support of ifosfamide/carboplatin/etoposide chemotherapy..” Seminars in Oncology 22, no. 3 Suppl 7 (June 1995): 18–22.
    • Crawford, J. “Vinorelbine (Navelbine) in non-small cell lung cancer: future directions..” Seminars in Oncology 21, no. 5 Suppl 10 (October 1994): 85–88.
    • Crawford, J., and M. A. O’Rourke. “Vinorelbine (Navelbine)/carboplatin combination therapy: dose intensification with granulocyte colony-stimulating factor..” Seminars in Oncology 21, no. 5 Suppl 10 (October 1994): 73–78.
    • Deutsch, M., J. Crawford, K. Leopold, W. Wolfe, W. Foster, J. Herndon, S. Blackwell, and R. Yost. “Phase II study of neoadjuvant chemotherapy and radiation therapy with thoracotomy in the treatment of clinically staged IIIA non-small cell lung cancer..” Cancer 74, no. 4 (August 1994): 1243–52. https://doi.org/10.1002/1097-0142(19940815)74:4<1243::aid-cncr2820740411>3.0.co;2-d.
       Full Text
    • Brizel, D. M., J. P. Gockerman, J. Crawford, J. W. Hathorn, J. O. Moore, B. Osborne, and L. R. Prosnitz. “A pilot study of etoposide, vinblastine, and doxorubicin plus involved field irradiation in advanced, previously untreated Hodgkin's disease..” Cancer 74, no. 1 (July 1994): 159–63. https://doi.org/10.1002/1097-0142(19940701)74:1<159::aid-cncr2820740125>3.0.co;2-x.
       Full Text
    • Hollen, P. J., R. J. Gralla, M. G. Kris, C. Cox, C. P. Belani, S. M. Grunberg, J. Crawford, and J. A. Neidhart. “Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies. Psychometric assessment of the Lung Cancer Symptom Scale..” Cancer 73, no. 8 (April 1994): 2087–98. https://doi.org/10.1002/1097-0142(19940415)73:8<2087::aid-cncr2820730813>3.0.co;2-x.
       Full Text
    • Morstyn, G., S. Brown, M. Gordon, J. Crawford, G. Demetri, W. Rich, B. McGuire, M. Foote, and I. McNiece. “Stem cell factor is a potent synergistic factor in hematopoiesis..” Oncology 51, no. 2 (March 1994): 205–14. https://doi.org/10.1159/000227335.
       Full Text
    • Crawford, J., H. Ozer, R. Stoller, D. Johnson, G. Lyman, I. Tabbara, M. Kris, et al. “Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer.” Clinical Infectious Diseases 18 (January 1, 1994): S189–96. https://doi.org/10.1093/clinids/18.Supplement_2.S189.
       Full Text
    • Johnson, D. H., D. Bass, L. H. Einhorn, J. Crawford, C. A. Perez, A. Bartolucci, G. A. Omura, and F. A. Greco. “Combination chemotherapy with or without thoracic radiotherapy in limited-stage small-cell lung cancer: a randomized trial of the Southeastern Cancer Study Group..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 11, no. 7 (July 1993): 1223–29. https://doi.org/10.1200/jco.1993.11.7.1223.
       Full Text
    • Rimer, B. K., D. Herman, J. Crawford, and S. Blackwell. “Lung cancer in North Carolina..” North Carolina Medical Journal 54, no. 7 (July 1993): 334–40.
    • Bowden, M., J. Crawford, H. J. Cohen, and O. Noyama. “A comparative study of monoclonal gammopathies and immunoglobulin levels in Japanese and United States elderly..” Journal of the American Geriatrics Society 41, no. 1 (January 1993): 11–14. https://doi.org/10.1111/j.1532-5415.1993.tb05940.x.
       Full Text
    • Case, D. C., M. C. Gerber, R. A. Gams, J. Crawford, M. L. Votaw, C. S. Higano, B. T. Pruitt, and J. Gould. “Phase II study of intravenous idarubicin in unfavorable non-Hodgkin's lymphoma..” Leuk Lymphoma 10 Suppl (1993): 73–79. https://doi.org/10.3109/10428199309149116.
       Full Text  Link to Item
    • Deutsch, M. A., K. A. Leopold, J. Crawford, W. Wolfe, W. Foster, S. Blackwell, and R. Yost. “Carboplatin, etoposide, and radiotherapy, followed by surgery, for the treatment of marginally resectable non-small cell lung cancer..” Cancer Treatment Reviews 19 Suppl C (January 1993): 53–62. https://doi.org/10.1016/0305-7372(93)90048-v.
       Full Text
    • Glaspy, J. A., G. Bleecker, J. Crawford, R. Stoller, and M. Strauss. “The impact of therapy with filgrastim (recombinant granulocyte colony-stimulating factor) on the health care costs associated with cancer chemotherapy..” European Journal of Cancer (Oxford, England : 1990) 29A Suppl 7 (January 1993): S23–30. https://doi.org/10.1016/0959-8049(93)90613-k.
       Full Text
    • Jr, D. C. C., M. C. Gerber, R. A. Gams, J. Crawford, M. L. Votaw, C. S. Higano, B. T. Pruitt, and J. Gould. “Phase II study of intravenous idarubicin in unfavorable non-Hodgkin's lymphoma.” Leukemia and Lymphoma 10, no. SUPPL. (1993): 73–79.
    • Kavanagh, B. D., G. S. Montana, J. Crawford, W. G. Wolfe, and M. S. Anscher. “Long‐term results of combined modality therapy for esophageal cancer.” Radiation Oncology Investigations 1, no. 4 (January 1, 1993): 227–34. https://doi.org/10.1002/roi.2970010406.
       Full Text
    • Case, D. C., M. C. Gerber, R. A. Gams, J. Crawford, M. L. Votaw, C. S. Higano, B. T. Pruitt, and J. Gould. “Phase II study of intravenous idarubicin in unfavorable non-Hodgkin's lymphoma..” Cancer Research 52, no. 14 (July 1992): 3871–74.
    • Panella, T. J., D. C. Smith, S. C. Schold, M. P. Rogers, E. P. Winer, R. L. Fine, J. Crawford, J. E. Herndon, and D. L. Trump. “Modulation of O6-alkylguanine-DNA alkyltransferase-mediated carmustine resistance using streptozotocin: a phase I trial..” Cancer Research 52, no. 9 (May 1992): 2456–59.
    • Roth, B. J., D. H. Johnson, L. H. Einhorn, L. P. Schacter, N. C. Cherng, H. J. Cohen, J. Crawford, J. A. Randolph, J. L. Goodlow, and G. O. Broun. “Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 10, no. 2 (February 1992): 282–91. https://doi.org/10.1200/jco.1992.10.2.282.
       Full Text
    • Blackwell, S., and J. Crawford. “Colony-stimulating factors: clinical applications..” Pharmacotherapy 12, no. 2 Pt 2 (January 1992): 20S-31S.
    • Crawford, J., and M. R. Green. “The role of colony stimulating factors as an adjunct to lung cancer chemotherapy: A commentary.” Lung Cancer 8, no. 3–4 (January 1, 1992): 153–58. https://doi.org/10.1016/0169-5002(92)90002-2.
       Full Text
    • Kavanagh, B., M. Anscher, K. Leopold, M. Deutsch, E. Gaydica, R. Dodge, K. Allen, D. Allen, W. Staub, and G. Montana. “Patterns of failure following combined modality therapy for esophageal cancer, 1984-1990..” International Journal of Radiation Oncology, Biology, Physics 24, no. 4 (January 1992): 633–42.
    • Crawford, J., H. Ozer, R. Stoller, D. Johnson, G. Lyman, I. Tabbara, M. Kris, J. Grous, V. Picozzi, and G. Rausch. “Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer..” The New England Journal of Medicine 325, no. 3 (July 1991): 164–70. https://doi.org/10.1056/nejm199107183250305.
       Full Text
    • Currie, M. S., D. L. Simel, R. H. Christenson, C. Holmes, J. Crawford, H. J. Cohen, and K. M. Rao. “Anti-inflammatory effects of pentoxifylline in claudication..” The American Journal of the Medical Sciences 301, no. 2 (February 1991): 85–90. https://doi.org/10.1097/00000441-199102000-00002.
       Full Text
    • Brizel, D. M., E. P. Winer, L. R. Prosnitz, J. Scott, J. Crawford, J. O. Moore, and J. P. Gockerman. “Improved survival in advanced Hodgkin's disease with the use of combined modality therapy..” Int J Radiat Oncol Biol Phys 19, no. 3 (September 1990): 535–42.
       Link to Item
    • Rao, K. M., D. L. Simel, H. J. Cohen, J. Crawford, and M. S. Currie. “Effects of pentoxifylline administration on blood viscosity and leukocyte cytoskeletal function in patients with intermittent claudication..” The Journal of Laboratory and Clinical Medicine 115, no. 6 (June 1990): 738–44.
    • Currie, M. S., M. Vala, D. S. Pisetsky, C. S. Greenberg, J. Crawford, and H. J. Cohen. “Correlation between erythrocyte CR1 reduction and other blood proteinase markers in patients with malignant and inflammatory disorders..” Blood 75, no. 8 (April 1990): 1699–1704.
    • Currie, M. S., K. M. Rao, J. Padmanabhan, A. Jones, J. Crawford, and H. J. Cohen. “Stimulus-specific effects of pentoxifylline on neutrophil CR3 expression, degranulation, and superoxide production..” Journal of Leukocyte Biology 47, no. 3 (March 1990): 244–50. https://doi.org/10.1002/jlb.47.3.244.
       Full Text
    • Kent, E. F., J. Crawford, H. J. Cohen, and R. H. Buckley. “Development of multiple monoclonal serum immunoglobulins (multiclonal gammopathy) following both HLA-identical unfractionated and T cell-depleted haploidentical bone marrow transplantation in severe combined immunodeficiency..” Journal of Clinical Immunology 10, no. 2 (March 1990): 106–14. https://doi.org/10.1007/bf00918192.
       Full Text
    • Crawford, J., S. Oates, L. A. Wolfe, and H. J. Cohen. “An in vitro analogue of immune dysfunction with altered immunoglobulin production in the aged..” Journal of the American Geriatrics Society 37, no. 12 (December 1989): 1140–46. https://doi.org/10.1111/j.1532-5415.1989.tb06678.x.
       Full Text
    • Meadows, L. M., W. R. Rosse, J. O. Moore, J. Crawford, J. Laszlo, and R. E. Kaufman. “Hodgkin's disease presenting as myelofibrosis..” Cancer 64, no. 8 (October 1989): 1720–26. https://doi.org/10.1002/1097-0142(19891015)64:8<1720::aid-cncr2820640828>3.0.co;2-l.
       Full Text
    • Carter, P. W., H. J. Cohen, and J. Crawford. “Hyperviscosity syndrome in association with kappa light chain myeloma..” The American Journal of Medicine 86, no. 5 (May 1989): 591–95. https://doi.org/10.1016/0002-9343(89)90392-6.
       Full Text
    • Rao, K. M., J. Crawford, M. S. Currie, and H. J. Cohen. “Actin depolymerization and inhibition of capping induced by pentoxifylline in human lymphocytes and neutrophils..” Journal of Cellular Physiology 137, no. 3 (December 1988): 577–82. https://doi.org/10.1002/jcp.1041370326.
       Full Text
    • Olsen, E. A., J. R. Crawford, and R. T. Vollmer. “Sinus histiocytosis with massive lymphadenopathy. Case report and review of a multisystemic disease with cutaneous infiltrates..” Journal of the American Academy of Dermatology 18, no. 6 (June 1988): 1322–32. https://doi.org/10.1016/s0190-9622(88)70142-5.
       Full Text
    • O’Rourke, M. A., and J. Crawford. “Lung cancer in the elderly..” Comprehensive Therapy 14, no. 6 (June 1988): 47–54.
    • Simel, D. L., E. R. DeLong, J. R. Feussner, J. B. Weinberg, and J. Crawford. “Erythrocyte anisocytosis. Visual inspection of blood films vs automated analysis of red blood cell distribution width..” Archives of Internal Medicine 148, no. 4 (April 1988): 822–24. https://doi.org/10.1001/archinte.1988.00380040062012.
       Full Text
    • Einhorn, L. H., J. Crawford, R. Birch, G. Omura, D. H. Johnson, and F. A. Greco. “Cisplatin plus etoposide consolidation following cyclophosphamide, doxorubicin, and vincristine in limited small-cell lung cancer..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 6, no. 3 (March 1988): 451–56. https://doi.org/10.1200/jco.1988.6.3.451.
       Full Text
    • O’Rourke, M. A., and J. Crawford. “Lung cancer in the elderly..” Clinics in Geriatric Medicine 3, no. 4 (November 1987): 595–623. https://doi.org/10.1016/s0749-0690(18)30778-x.
       Full Text
    • Crawford, J., and H. J. Cohen. “Relationship of cancer and aging..” Clinics in Geriatric Medicine 3, no. 3 (August 1987): 419–32. https://doi.org/10.1016/s0749-0690(18)30791-2.
       Full Text
    • Eaton, A. M., H. Serota, G. W. Kernodle, J. P. Uglietta, J. Crawford, and W. J. Fulkerson. “Pulmonary hypertension secondary to serum hyperviscosity in a patient with rheumatoid arthritis..” The American Journal of Medicine 82, no. 5 (May 1987): 1039–45. https://doi.org/10.1016/0002-9343(87)90172-0.
       Full Text
    • Crawford, J., M. K. Eye-Boland, and H. J. Cohen. “Clinical utility of erythrocyte sedimentation rate and plasma protein analysis in the elderly..” The American Journal of Medicine 82, no. 2 (February 1987): 239–46. https://doi.org/10.1016/0002-9343(87)90063-5.
       Full Text
    • Crawford, J., M. K. Eye, and H. J. Cohen. “Evaluation of monoclonal gammopathies in the "well" elderly..” The American Journal of Medicine 82, no. 1 (January 1987): 39–45. https://doi.org/10.1016/0002-9343(87)90375-5.
       Full Text
    • Sanfilippo, F., J. Crawford, and G. Ness. “Influence of donor-specific blood transfusions on host cellular immune responsiveness.” Transplantation Proceedings 18, no. 4 (January 1, 1986): 692–94.
    • Crawford, J., and H. J. Cohen. “The essential role of L-glutamine in lymphocyte differentiation in vitro..” Journal of Cellular Physiology 124, no. 2 (August 1985): 275–82. https://doi.org/10.1002/jcp.1041240216.
       Full Text
    • Crawford, J., E. B. Cox, and H. J. Cohen. “Evaluation of hyperviscosity in monoclonal gammopathies..” The American Journal of Medicine 79, no. 1 (July 1985): 13–22. https://doi.org/10.1016/0002-9343(85)90540-6.
       Full Text
    • Crawford, J., and H. J. Cohen. “Aging and neoplasia..” Annual Review of Gerontology & Geriatrics 4 (January 1984): 3–32.
    • Crawford, J., and H. J. Cohen. “An approach to monoclonal gammopathies in the elderly..” Geriatrics 37, no. 10 (October 1982): 97–112.
       Link to Item
    • ARIEFF, A. J., J. ADAMS, and J. CRAWFORD. “Treatment of recurrent mental depression with imipramine..” The Illinois Medical Journal 120 (October 1961): 245–48.
    • ARIEFF, A. J., J. CRAWFORD, J. ADAMS, and D. SMITH. “Glucagon in insulin coma therapy: its use in a small psychiatric unit of a general hospital..” Quarterly Bulletin. Northwestern University (Evanston, Ill.). Medical School 34 (January 1960): 7–10.
    • Crawford, J. “Docetaxel/vinorelbine combination therapy in non-small-cell lung cancer.” Oncology 11, no. 7 SUPPL. (August 27, 1997): 35–40.
    • Stein, R. S., J. T. Hamm, G. M. Higa, R. M. Auchter, J. Crawford, and J. A. Glaspy. “G-CSF for fever and neutropenia induced by chemotherapy.” New England Journal of Medicine 326, no. 4 (January 23, 1992): 269–70. https://doi.org/10.1056/NEJM199201233260412.
       Full Text

  • Book Sections

    • McKinney, M. S., and J. Crawford. “Erythropoiesis-stimulating agents in older adults with cancer.” In Practical Geriatric Oncology, 338–50, 2010. https://doi.org/10.1017/CBO9780511763182.024.
       Full Text
    • Crawford, J. “Myeloid growth factors.” In Cancer Supportive Care: Advances in Therapeutic Strategies, 115–34, 2008.
    • Dale, D. C., J. Crawford, and G. H. Lyman. “Neutropenia and its complications.” In Cancer Supportive Care: Advances in Therapeutic Strategies, 59–72, 2008.
    • Lacerna, L., W. P. Sheridan, R. Basser, C. Glenn Begley, J. Crawford, G. Demetri, C. H. Moskowitz, G. Tricot, A. Weaver, and J. A. Glaspy. “Stem cell factor.” In Hematopoietic Stem Cell Transplantation, 31–46, 2000.

  • Other Articles

    • Stevenson, Marvaretta, William Mostertz, Chaitanya R. Acharya, William Kim, Kelli Walters, William Barry, Kristin Higgins, et al. “Retraction: characterizing the clinical relevance of an embryonic stem cell phenotype in lung adenocarcinoma..” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, March 2012. https://doi.org/10.1158/1078-0432.ccr-12-0337.
       Full Text

  • Conference Papers

    • Cupp, Julia, Eva Culakova, Marek S. Poniewierski, David C. Dale, Gary H. Lyman, and Jeffrey Crawford. “Analysis of Factors Associated With In-hospital Mortality in Lung Cancer Chemotherapy Patients With Neutropenia..” In Clinical Lung Cancer, 19:e163–69, 2018. https://doi.org/10.1016/j.cllc.2017.10.013.
       Full Text
    • Lyman, Gary H., Jeffrey Crawford, Dianne Tomita, Sadie Whittaker, and David C. Dale. “Changing patterns of chemotherapy relative dose intensity and supportive care for aggressive B-cell non-Hodgkin lymphoma..” In Leukemia & Lymphoma, 57:283–90, 2016. https://doi.org/10.3109/10428194.2015.1045894.
       Full Text
    • Zhou, T., P. Wright, J. Crawford, G. McKinnon, and Y. Zhang. “MEMS 3D optical mirror/scanner.” In Proceedings  International Conference on Mems, Nano and Smart Systems, Icmens 2003, 222–26, 2003. https://doi.org/10.1109/ICMENS.2003.1221996.
       Full Text

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.